FDA Guides Faster Path for Generic Drug Approvals
Published Date: 6/16/2025
Notice
Summary
The FDA just released new rules to help generic drug makers send important info about their factories before submitting priority drug applications. This speeds up reviews and helps the FDA set clear goals for fast-tracking these drugs. If you’re in the generic drug business, get ready to share your facility details early to keep things moving smoothly and meet new deadlines tied to the latest fee program.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Send Factory Details Before Priority ANDAs
The FDA's final guidance explains what facility information generic drug makers must send in a pre-submission facility correspondence (PFC) before filing a prioritized Abbreviated New Drug Application (ANDA). The guidance explains how FDA will use that facility information to set a review goal for a priority ANDA.
Guidance Implements GDUFA III Enhancement
The guidance incorporates a program enhancement agreed between FDA and industry as part of the Generic Drug User Fee Amendments (GDUFA) reauthorization and described in the GDUFA III commitment letter for Fiscal Years 2023-2027. The document finalizes the draft guidance that was issued on December 5, 2022.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in